Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)

This study has been completed.
The Leukemia and Lymphoma Society
Therapeutics, Inc.
Veristat, Inc.
Information provided by (Responsible Party):
TetraLogic Pharmaceuticals Identifier:
First received: September 9, 2011
Last updated: August 7, 2014
Last verified: August 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2013
  Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)